Investigational drug · Phase 2
KN060
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for End-Stage Renal Disease Requiring Haemodialysis, Knee Arthroplasty, Total.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 1, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
3
Any phase or sponsor naming "KN060"
First trial start
2023
Dec 20, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "KN060", any sponsor or status.
Conditions studied
As listed on its trial records.
- End-Stage Renal Disease Requiring Haemodialysis
- Knee Arthroplasty, Total
Approved drugs for the same conditions: Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "KN060" as an intervention, largest first.
- Factor XI inhibiTion for the Prevention of Venous Thromboembolism in Patients Undergoing Total Knee ArthroplastyPivotal-lookingActive, not recruiting
Suzhou Alphamab Co., Ltd.Industry
NCT06180889 · 241 participants · Start Dec 20, 2023 · Primary completion Dec 15, 2025
Drug: Enoxaparin; KN060 Low and 2 more · For: Knee Arthroplasty, Total
Sites: Shanghai, China
Suzhou Alphamab Co., Ltd.Industry
NCT07191899 · 60 participants (planned) · Start Aug 5, 2025 · Primary completion Dec 30, 2026
Drug: KN060; 0.9% Sodium Chloride Injection · For: Hypertension
Sites: Shanghai, China
Suzhou Alphamab Co., Ltd.Industry
NCT07201467 · 12 participants (planned) · Start Aug 22, 2025 · Primary completion Aug 15, 2027
Drug: KN060 · For: End-Stage Renal Disease Requiring Haemodialysis
Sites: Beijing, China
Newest research
PubMed records naming it or its code names, newest first.
- Safety, tolerability, pharmacokinetics, and pharmacodynamics of KN060, a humanized anti-FXI/FXIa dual-domain antibody, following single ascending doses in healthy Chinese subjects.
Huang J, Liu J, Liu Y, et al. · Res Pract Thromb Haemost 2026
- KN060-a humanized dual-domain antibody simultaneously targeting FXI-A2/A3 epitopes: Pioneering the anti-coagulation factor XI strategy for Aterial hypertension - Evidence from preclinical models.
Yu X, Li Q, Zhang D, et al. · Eur J Pharmacol 2025
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.